GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Agile Therapeutics Inc (OTCPK:AGRX) » Definitions » E10

AGRX (Agile Therapeutics) E10 : $-1,641.40 (As of Jun. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Agile Therapeutics E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Agile Therapeutics's adjusted earnings per share data for the three months ended in Jun. 2024 was $-1.730. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-1,641.40 for the trailing ten years ended in Jun. 2024.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2025-03-13), Agile Therapeutics's current stock price is $1.51. Agile Therapeutics's E10 for the quarter that ended in Jun. 2024 was $-1,641.40. Agile Therapeutics's Shiller PE Ratio of today is .


Agile Therapeutics E10 Historical Data

The historical data trend for Agile Therapeutics's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Agile Therapeutics E10 Chart

Agile Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - -2,056.51 -1,709.13

Agile Therapeutics Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,876.40 -1,785.43 -1,709.13 -1,752.16 -1,641.40

Competitive Comparison of Agile Therapeutics's E10

For the Drug Manufacturers - Specialty & Generic subindustry, Agile Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Agile Therapeutics's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Agile Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Agile Therapeutics's Shiller PE Ratio falls into.



Agile Therapeutics E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Agile Therapeutics's adjusted earnings per share data for the three months ended in Jun. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Jun. 2024 (Change)*Current CPI (Jun. 2024)
=-1.73/132.5538*132.5538
=-1.730

Current CPI (Jun. 2024) = 132.5538.

Agile Therapeutics Quarterly Data

per share eps CPI Adj_EPS
201409 -680.000 100.428 -897.526
201412 -740.000 99.070 -990.109
201503 -800.000 99.621 -1,064.464
201506 -760.000 100.684 -1,000.566
201509 -840.000 100.392 -1,109.110
201512 -340.000 99.792 -451.620
201603 -540.000 100.470 -712.439
201606 -580.000 101.688 -756.049
201609 -540.000 101.861 -702.713
201612 -360.000 101.863 -468.468
201703 -520.000 102.862 -670.100
201706 -520.000 103.349 -666.943
201709 -440.000 104.136 -560.074
201712 -340.000 104.011 -433.303
201803 -400.000 105.290 -503.578
201806 -320.000 106.317 -398.970
201809 -220.000 106.507 -273.803
201812 -220.000 105.998 -275.117
201903 -260.000 107.251 -321.341
201906 -160.000 108.070 -196.250
201909 -160.000 108.329 -195.779
201912 -200.000 108.420 -244.519
202003 -200.000 108.902 -243.438
202006 -240.000 108.767 -292.486
202009 -360.000 109.815 -434.544
202012 -400.000 109.897 -482.466
202103 -400.000 111.754 -474.447
202106 -400.000 114.631 -462.539
202109 -360.000 115.734 -412.318
202112 -400.000 117.630 -450.750
202203 -166.680 121.301 -182.142
202206 -57.290 125.017 -60.744
202209 -8.010 125.227 -8.479
202212 -5.000 125.222 -5.293
202303 -5.910 127.348 -6.152
202306 -2.150 128.729 -2.214
202309 -0.270 129.860 -0.276
202312 -1.410 129.419 -1.444
202403 0.280 131.776 0.282
202406 -1.730 132.554 -1.730

Add all the adjusted EPS together and divide 10 will get our e10.


Agile Therapeutics  (OTCPK:AGRX) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Agile Therapeutics E10 Related Terms

Thank you for viewing the detailed overview of Agile Therapeutics's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Agile Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
500 College Road East, Suite 310, Princeton, NJ, USA, 08540
Agile Therapeutics Inc is a women's healthcare company to fulfill the unmet health needs of women. Its product candidates are designed to provide women with contraceptive options. The firm's initial product, Twirla, (levonorgestrel and ethinyl estradiol) transdermal system is a non-daily prescription contraceptive. Twirla is based on proprietary transdermal patch technology, called Skinfusion, which is designed to allow drug delivery through the skin. The Company views its operations and manages its business in one operating and reporting segment, which is the business of commercializing its transdermal patch for use in contraception.
Executives
Scott M Coiante officer: Chief Financial Officer 101 POOR FARM ROAD 3RD FLOOR, PRINCETON NJ 08540
Josephine Torrente director 101 POOR FARM ROAD, PRINCETON NY 08540
Sandra Carson director C/O AGILE THERAPEUTICS, INC., 101 POOR FARM ROAD, PRINCETON NJ 08540
John W Hubbard director 101 POOR FARM ROAD 3RD FLOOR, PRINCETON NJ 08540
Fischer Seth H.z. director C/O TRIUS THERAPEUTICS, INC., 6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121
Sharon Surrey Barbari director 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Amy Welsh officer: Chief Commercial Officer 500 COLLEGE ROAD EAST, SUITE 310, C/O AGILE THERAPEUTICS, INC., PRINCETON NJ 08540
Alfred Altomari director, officer: Chief Executive Officer C/O AGILE THERAPEUTICS, INC., 101 POOR FARM ROAD, PRINCETON NJ 08540
Perceptive Life Sciences Master Fund Ltd 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Dennis Reilly officer: Chief Financial Officer 600 COLLEGE ROAD EAST, PRINCETON NJ 08540
Jason Butch officer: Principal Accounting Officer 101 POOR FARM ROAD, PRINCETON NJ 08540
Paul Korner officer: Sr. VP & Chief Medical Officer C/O ARDELYX, INC., 34175 ARDENWOOD BLVD, SUITE 200, FREMONT CA 94555
Abhijeet J Lele director, See remarks C/O EP MEDYSTEMS, 575 RTE 73 N, WEST BERLIN NJ 08091
Perceptive Advisors Llc 10 percent owner 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Joseph Edelman 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003